Treatment results of neoadjuvant chemoradiotherapy followed by radical esophagectomy in patients with initially inoperable thoracic esophageal cancer
- PMID: 29080946
- DOI: 10.1007/s11604-017-0693-0
Treatment results of neoadjuvant chemoradiotherapy followed by radical esophagectomy in patients with initially inoperable thoracic esophageal cancer
Abstract
Purpose: We evaluated the effectiveness of neoadjuvant chemoradiotherapy (CRT) followed by esophagectomy for cT4 esophageal cancer or lymph node metastases (LNM) invading adjacent structures.
Materials and methods: We retrospectively evaluated 42 consecutive patients with thoracic esophageal cancer who underwent CRT followed by esophagectomy between 2008 and 2013. All were initially considered to be unresectable because of cT4 (n = 32) disease or LN invasion (n = 10). Radiotherapy was administered at 41.4 Gy/23 fr with concurrent chemotherapy. At completion of CRT, restaging was performed using computed tomography (CT).
Results: All cT4 tumors were downstaged, LNM invading to adjacent structures were considered to be released, and subtotal esophagectomy was performed. The median follow-up period was 42 months. The curative resection (R0) rate was 94% in cT4 group and 70% in LN invasion group. The 3-year overall survival (OS) and 3-year locoregional control (LRC) rates were 65-80% in the cT4 group and 50-67% in LN invasion group, respectively.
Conclusions: The cT4 group showed good rates of R0, OS, and LRC. Surgical resection should be an effective option when downstaging is achieved by CRT for patients with initially inoperable thoracic esophageal cancer.
Keywords: Chemoradiotherapy; Esophageal cancer; Esophagectomy; Neoadjuvant therapy; cT4.
Similar articles
-
Comparison of neoadjuvant chemotherapy versus upfront surgery with or without chemotherapy for patients with clinical stage III esophageal squamous cell carcinoma.Dis Esophagus. 2017 Feb 1;30(2):1-8. doi: 10.1111/dote.12473. Dis Esophagus. 2017. PMID: 26919154
-
Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):427-36. doi: 10.1016/j.ijrobp.2004.03.033. Int J Radiat Oncol Biol Phys. 2004. PMID: 15380576
-
A retrospective comparison of neoadjuvant chemoradiotherapy regimens for locally advanced esophageal cancer.Dis Esophagus. 2017 Jul 1;30(7):1-8. doi: 10.1093/dote/dox025. Dis Esophagus. 2017. PMID: 28475728
-
Does timing of esophagectomy following neoadjuvant chemoradiation affect outcomes? A meta-analysis.Int J Surg. 2018 Nov;59:11-18. doi: 10.1016/j.ijsu.2018.09.013. Epub 2018 Sep 24. Int J Surg. 2018. PMID: 30261331 Review.
-
Recent progress in multidisciplinary treatment for patients with esophageal cancer.Surg Today. 2020 Jan;50(1):12-20. doi: 10.1007/s00595-019-01878-7. Epub 2019 Sep 18. Surg Today. 2020. PMID: 31535225 Free PMC article. Review.
Cited by
-
Association between interstitial lung abnormality and mortality in patients with esophageal cancer.Jpn J Radiol. 2024 Aug;42(8):841-851. doi: 10.1007/s11604-024-01563-x. Epub 2024 Apr 25. Jpn J Radiol. 2024. PMID: 38658500 Free PMC article.
-
Endobronchial Ultrasonography to Assess and Evaluate Tracheobronchial Tree Invasion in cT4b Esophageal Cancer Patients Treated with Definitive Chemoradiotherapy: Assessment of Resectability.Ann Surg Oncol. 2025 Jan;32(1):284-292. doi: 10.1245/s10434-024-15621-1. Epub 2024 Jul 6. Ann Surg Oncol. 2025. PMID: 38971953 Free PMC article.
-
Short-and middle-term outcomes of robot-assisted minimally invasive esophagectomy for highly locally advanced esophageal cancer with stage cT3 borderline and cT4b at initial diagnosis.Surg Endosc. 2025 May;39(5):2994-3005. doi: 10.1007/s00464-025-11666-9. Epub 2025 Mar 21. Surg Endosc. 2025. PMID: 40116900
-
Esophageal cancer practice guidelines 2022 edited by the Japan esophageal society: part 1.Esophagus. 2023 Jul;20(3):343-372. doi: 10.1007/s10388-023-00993-2. Epub 2023 Mar 18. Esophagus. 2023. PMID: 36933136 Free PMC article. No abstract available.
-
Longer interval between neoadjuvant chemoradiotherapy and surgery is associated with improved pathological response, but does not accurately estimate survival in patients with resectable esophageal cancer.Oncol Lett. 2023 Mar 3;25(4):155. doi: 10.3892/ol.2023.13741. eCollection 2023 Apr. Oncol Lett. 2023. PMID: 36936022 Free PMC article.
References
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials